Sertraline
| Evidence Level: L1 | Predicted Indications: 8 |
Table of Contents
Sertraline: Evaluating Repurposing Potential for Agoraphobia
One-Sentence Summary
Sertraline is a selective serotonin reuptake inhibitor (SSRI) with an established evidence base — reflected in completed Phase 4 trials — in panic disorder and social phobia. The TxGNN model predicts additional efficacy in Agoraphobia, a condition that is clinically highly comorbid with panic disorder, and this is currently the best-supported of eight TxGNN-predicted candidates, with 4 clinical trials (including a completed Phase 4 head-to-head RCT) and 20 publications, several at systematic review/meta-analysis level.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (drug-level original indication data absent). Trial evidence indicates sertraline has established use in panic disorder and social phobia. |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not provided in this evidence pack. Based on the information available, sertraline is an SSRI; its serotonergic mechanism underlies established efficacy in panic disorder and social phobia, evidenced here by a completed Phase 4 RCT (NCT00677352, sertraline vs paroxetine, n=321).
Agoraphobia and panic disorder are closely linked conditions — agoraphobia is clinically highly comorbid with panic disorder, and SSRIs are already first-line pharmacotherapy for that combined presentation. This mechanistic and clinical overlap is the basis for the TxGNN prediction: rather than an unrelated new target, agoraphobia sits directly adjacent to sertraline’s existing anxiety-disorder evidence base, which is reflected in the systematic reviews and network meta-analyses of “panic disorder with or without agoraphobia” identified below.
It is worth noting that TxGNN generated seven further candidate indications for sertraline in this evidence pack (mostly personality disorders), but these lack direct mechanistic rationale or supporting evidence and are not recommended to proceed (see table at the end of this report).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00677352 | Phase 4 | Completed | 321 | Randomised, double-blind, multicentre head-to-head comparison of sertraline vs paroxetine for panic disorder; direct RCT evidence relevant to the panic/agoraphobia spectrum. |
| NCT00182533 | Phase 4 | Terminated | 170 | Sertraline in generalized social phobia with comorbidities; trial halted, limits strength of conclusions. |
| NCT05210153 | N/A | Unknown | 148 | Plasma drug level monitoring and CYP2C19 genotyping for sertraline dose personalisation in depression; supportive pharmacokinetic data only, not an efficacy endpoint trial. |
| NCT05930912 | N/A | Unknown | 1 | Psychoanalytic treatment study in autism spectrum disorder with comorbid anxiety; n=1, minimal direct relevance. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35045991 | 2022 | Systematic Review/Network Meta-analysis | BMJ | Compares SSRIs including sertraline for remission rates and adverse event risk in panic disorder with or without agoraphobia. |
| 38014714 | 2023 | Network Meta-analysis | Cochrane Database Syst Rev | Network meta-analysis of pharmacological treatments for panic disorder in adults. |
| 16053461 | 2005 | RCT | Bosnian J Basic Med Sci | 12-week placebo-controlled trial of sertraline vs alprazolam specifically evaluating panic attacks, agoraphobia and anticipatory anxiety (ICD-10). |
| 37676054 | 2023 | Systematic Review | Expert Rev Neurother | Systematic review of pharmacological management of panic disorder in older patients. |
| 12191627 | 2002 | RCT (secondary analysis) | J Psychiatr Res | Pooled analysis of 4 sertraline/placebo trials (n=544) in panic disorder with or without agoraphobia; early improvement predicts remission. |
| 16505130 | 2006 | RCT | Am J Geriatr Psychiatry | RCT comparing CBT vs sertraline for anxiety disorders in older adults. |
| 16292466 | 2006 | Pooled Cohort Analysis | Arch Womens Ment Health | Pooled sertraline treatment data examining sex differences in panic disorder with/without agoraphobia. |
| 36573969 | 2022 | Review | JAMA | General review of anxiety disorders, including agoraphobia and pharmacological management. |
| 38299123 | 2024 | Review (case-based) | Epilepsy Behav Rep | Case discussion of panic disorder progressing to agoraphobia, managed with psychopharmacological treatment. |
| 11110016 | 2000 | Review | Int Clin Psychopharmacol | Review of SSRIs, including sertraline, in the treatment of panic disorder and agoraphobia. |
UK Market Information
No marketing authorisation records are held in this evidence pack. UK market status is recorded as Not marketed (0 licenses on file).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Other TxGNN-Predicted Indications Considered (Not Recommended)
For transparency, this evidence pack contained seven further TxGNN-predicted indications for sertraline, all with substantially weaker support:
| Disease | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|
| Schizotypal personality disorder | 99.93% | L4 | Research Question |
| Dependent personality disorder | 99.21% | L4 | Research Question |
| Paranoid personality disorder | 99.93% | L5 | Hold |
| Schizoid personality disorder | 99.93% | L5 | Hold |
| Histrionic personality disorder | 99.93% | L5 | Hold |
| Narcissistic personality disorder | 99.14% | L5 | Hold |
| Benign paroxysmal torticollis of infancy | 99.55% | L5 | Hold |
These lack direct mechanistic rationale or disease-specific clinical evidence and are not carried forward in this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Agoraphobia is closely linked to panic disorder, for which sertraline already has completed Phase 4 RCT and systematic review/meta-analysis level evidence. However, no identified trial enrols agoraphobia as the primary diagnosis independent of panic disorder, so the evidence remains indirect.
To proceed, the following is needed:
- Product label safety data (key warnings, contraindications) — currently a blocking data gap
- Detailed mechanism of action documentation for sertraline
- Confirmation of UK marketing authorisation pathway, given current “Not marketed” status
- A trial or evidence synthesis with agoraphobia as the primary (rather than comorbid) endpoint
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.